

Addendum

Addendum: Liquid biopsy and multi-analyte testing guided treatment of *HER2* positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy**Rajnish Nagarkar¹, Darshana Patil², Sewanti Limaye³, Pradip Devhare², Ashwini Ghaisas², Navin Srivastava², Sachin Apurwa², Sanket Patil², Jinumary John², Zarrine Raazi², Aditya Shreenivas⁴, Janani Sambath^{5,6}, Ajay Srinivasan², Prashant Kumar^{2,5,6}, Dadasaheb Akolkar² and Rajan Datar²**¹HCG Manavata Cancer Centre, Nasik, Maharashtra, India²Datar Cancer Genetics Limited, Nasik, Maharashtra, India³Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India⁴Department of Medical Oncology, Medical College Wisconsin, WI, USA⁵Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India⁶Manipal Academy of Higher Education, Manipal, Karnataka, India**Published:** November 02, 2022**Copyright:** © 2022 Nagarkar et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** The patient has previously consented to publication of de-identified findings.Original article: Oncotarget. 2020; 11:4195–4200. <https://doi.org/10.18632/oncotarget.27793>